Project Grant R03CA278603
Award Date
8/16/23
Completion Date
7/31/25
Dollars Obligated
$169K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $706,771 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to conduct a hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in Federally Qualified Health Centers in Tampa, Florida. The study aims to evaluate the impact of a precision prevention intervention to improve skin cancer prevention behaviors, such as...
This federal Project Grant award of $334,233, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, will support a comprehensive research study examining disparities in novel cancer therapies, the joint effects of cancer treatment and comorbidities, and multi-level contributors to cancer survival outcomes. The University of South Carolina, the prime awardee, will conduct innovative data linkages between the state cancer registry,...
The National Cancer Institute (NCI) awarded a 5-year, $162,160 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The Ohio State University to improve the assessment of patient-reported outcomes (PROs) among Black/African-American cancer patients. The research will involve qualitative interviews with Black cancer patients and their providers to understand barriers and facilitators to completing PROs and social determinants of health (SDH) measures. This knowledge will inform the...
This Project Grant award of $589,591 from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) supports a study to determine barriers leading to inferior survival for Black and Hispanic patients with Hodgkin lymphoma. The key products/services to be delivered include: Examining differences in the receipt and quality of Hodgkin lymphoma treatment for initial diagnosis and relapse, particularly for patients who have relapsed....
The National Cancer Institute (NCI) awarded a $549,962 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant, awarded from April 1, 2025 to March 31, 2030, will fund a research project to determine how antibodies and cellular ligands regulate the immunosuppressive function of the lymphocyte-activation gene 3 (LAG3) protein. The project aims to provide fundamental insights into...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will support a $734,942 research project over 5 years from August 2025 to July 2030. The research aims to evaluate how biological aging metrics, such as epigenetic clocks and leukocyte composition, are associated with cardiovascular disease (CVD) and mortality risk in breast cancer survivors. The project will...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Fred Hutchinson Cancer Center in Seattle, WA will support research to understand the pathogenesis of classic Hodgkin lymphoma in persons living with HIV (PLWH). The $176,000 award will fund a 2-year study to identify persistent transcriptomic changes in immune cells from benign lymph nodes of PLWH on combination antiretroviral therapy, and compare these findings to changes in classic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $691,118 in funding to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to establish a prospective cohort study of real-world multiple myeloma patients treated with chimeric antigen receptor (CAR) T-cell therapy. The study aims to evaluate the relationships between psychosocial factors (e.g., depression, anxiety, social support) and...
This Cooperative Agreement award of $860,545.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports the implementation and evaluation of a Comprehensive Survivorship Care (CSC) intervention across 14 Federally Qualified Health Centers (FQHCs) in South Florida. The project aims to train clinicians, implement the CSC intervention, and evaluate its effectiveness compared to standard survivorship care on patient outcomes such as...
This $1,500,000 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research by the University of Rochester to elucidate how key aspects of social connectedness, including structural characteristics, functional aspects, and quality of relationships in the social networks of older adults with advanced cancer, interact and influence end-of-life health behaviors. The study will focus on three critical behaviors - serious illness...